Sanofi US News
WEB6 days ago · Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com .
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB3 days ago · Dupixent is a key top-line driver for both Sanofi and Regeneron on strong demand trends. In the first half of 2024, Dupixent generated global product sales of $€6.1 billion, which were recorded ...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB6 days ago · Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U ...
Dupixent Gets FDA Approval for COPD - WebMD
WEB1 day ago · Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...
FDA approves Dupixent for chronic obstructive pulmonary disease
WEB1 day ago · by Lori Solomon. The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive ...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB6 days ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage alerts for this article
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBSep 27, 2013 · Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com .
Press Room - Sanofi US News
WEBMar 23, 2023 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA …
WEBMay 31 (Reuters) - Sanofi (SASY.PA) and partner Regeneron Pharmaceuticals (REGN.O) have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even...
Dupixent® - Pivotal Trial Results | Sanofi
WEBMar 23, 2006 · Dupixent® (dupilumab) shows promise as a groundbreaking biologic obtaining positive results in the pivotal trials. Learn more about these promising results.